KRAS and lung carcinoma: reported a synergistic phenomenon between oncogenic KRAS mutation and IGF2BP1 overexpression in murine and human lung carcinoma models: KRASG12V mutant/IGF2BP1 transgenic mice presented an accelerated tumour progression related with KRAS mRNA association to IGF2BP1 (Rosenfeld et al., 2019).